FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average b	ourden								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

								. ,												
1. Name and Address of Reporting Person*							2. Issuer Name and Ticker or Trading Symbol BIOGEN IDEC INC [BIIB]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Hamm Robert A</u>					=-	DIOGERTIDES II C DIID]									Dire	ctor	10% (Owner		
-						-									X		er (give title		Other (specify	
(Last)		3. Date of Earliest Transaction (Month/Day/Year) 03/20/2007									belo	,	below	,						
14 CAMBRIDGE CENTER										03/.		SVP, Immunology Business Unit								
(6)						4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) CAMBRIDGE MA 02142														X	,					
															Form filed by More than One Reporting Person					
(City)	(State) (Zip)															1 010				
			Table	e I - No	on-Deriv	ative	Sec	uritie	s Ac	quired	l, Di	sposed o	f, or E	Benef	cially	Own	ed			
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/						Year) Exec		Deemed cution Date, y nth/Day/Year)		3. Transaction Code (Instr. 8)				and 5) Secu Bene		ficially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
										Code	v	Amount	(A) or (D) Price		е	Trans	action(s) 3 and 4)		(Instr. 4)	
Common Stock 03/20/20					2007	007			S ⁽¹⁾		5,077	D	\$4	\$44.4789		,037.41	D			
			Tal	ble II -								osed of, convertib				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversid or Exercis Price of Derivative Security	e (Month/Day	y/Year)	3A. Dee Execution if any (Month/			Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exerc ion Da /Day/Y		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		Deri Sec (Ins	rice of vative urity r. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
						Code	v	(A) (D)		Date Exercisable		Expiration Date	Amor or Numi of Title Share		er					

Explanation of Responses:

1. Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

Remarks:

By: Robert Licht attorney-infact for: Robert Hamm

03/21/2007

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.